Genmab — Februar 2025
-
Darzalex udgjorde 65% af omsætningen i 2024
-
I øvrigt faldet støt fra 82% i 2021.
-
Jeg prøvede lige at sammenligne Darzelex andel af omsætningen de sidste 5 år. https://proinvestor.com/boards/124771/
-
https://seekingalpha.com/article/4758476-genmab-a-s-gmab-q4-2024-earnings-conference-call-transcript Genmab A/S (GMAB) Q4 2024 Earnings Conference Call Transcript
-
Blandt de aktier, der har stor indflydelse på indeksene, er Nvidia, som steg 2,6 procent til 138,85 dollar pr. Tesla er stort set uændret og handles til $355,84 per aktie. Apple er også i grønt for dagen, en stigning på 1,3 procent til $244,60 per aktie. På listen over aktier med den højeste handelsvolumen finder vi halvlederproducenten Super Micro Computers, som steg markant med 13,5 procent til 48,00 USD pr.
-
J&J’s Lazcluze, Genmab’s Tivdak, and More Up for MHLW Panel Review on Feb. 27 (Japan) https://pj.jiho.jp/article/252495
-
InnovaTV 205 Completion dates extended by > 1 year ; i can only imagine this being done to capture longer Overal Survival in the data than previously anticipated?
they stopped recruiting Jan23 https://clinicaltrials.gov/study/NCT03786081?tab=history&a=25&b=26&compareMode=sideBySide#version-content-panel -
Teknisk: Genmab løftes yderligere i USA efter dansk lukketid, trendvending på vej efter halvering de seneste år? https://proinvestor.com/investornyt/1278893/teknisk-genmab-loftes-yderligere-i-usa-efter-dansk-lukketid-trendvending-pa-vej-efter-halvering-de-seneste-ar
-
Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B-Cell Lymphoma https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3588
-
Genmab/Deutsche Bank: Kursmålet sænkes til 2100 kr. fra 2250 kr. - "køb" gentages https://proinvestor.com/investornyt/1279192/genmab-deutsche-bank-kursmalet-saenkes-til-2100-kr-fra-2250-kr-kob-gentages
-
Genmab - 2 neglebider uger med stor betydning https://proinvestor.com/boards/124798
-
Regimen may become new standard for relapsed/refractory diffuse large B-cell lymphoma https://www.healio.com/news/hematology-oncology/20250212/regimen-may-become-new-standard-for-relapsedrefractory-diffuse-large-bcell-lymphoma
-
“We expected the clinical outcomes to be good but were surprised about how good they were,” Joshua D. Brody, MD, director of the lymphoma immunotherapy program at The Tisch Cancer Institute at Mount Sinai, told Healio. “CD20xCD3 bispecific antibodies plus Gem-Ox will likely become a new standard of care for patients with relapsed/refractory DLCBL.”
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind